Afya Limited — FY2022 Form 20-F Summary
Reporting period: Fiscal year ended December 31, 2022. This is an annual report, not a standalone fourth-quarter filing; the supplied filing text does not provide a clear set of Q4-only results. Afya is a Brazil-focused medical education and digital health company reporting under IFRS in Brazilian reais (R$). U.S. dollar figures are convenience translations, not a separate reporting basis.
Business context
Afya operates undergraduate education, continuing education and digital services. Its revenue is concentrated in tuition, particularly medical and health-sciences courses. The company reported 58,200 undergraduate students at year-end, down 4.7% from 61,118 in 2021; growth in reported revenue also reflects acquisitions and therefore is not directly comparable across periods.
Key financial metrics
| Metric (R$ millions, except margins and ratios) | 2022 | 2021 | Change |
|---|---|---|---|
| Revenue | 2,329.1 | 1,719.4 | +35.5% |
| Gross profit | 1,469.5 | 1,067.1 | +37.7% |
| Gross margin | 63.1% | 62.1% | +1.0 percentage point |
| Operating income | 664.1 | 440.9 | +50.6% |
| Operating margin | 28.5% | 25.6% | +2.9 percentage points |
| Net income | 392.8 | 242.3 | +62.1% |
| Net margin | 16.9% | 14.1% | +2.8 percentage points |
| Adjusted EBITDA (non-GAAP) | 962.1 | 754.9 | +27.4% |
| Net cash from operating activities | 843.9 | 630.9 | +33.8% |
| Operating cash conversion ratio (non-GAAP) | 94.4% | 100.8% | Down 6.4 percentage points |
| Cash and cash equivalents, year-end | 1,093.1 | 748.6 | +46.0% |
| Loans and financing, year-end | 1,882.9 | 1,374.9 | +36.9% |
Margins and percentage changes above are calculated from the filing’s rounded figures. Finance result was a net expense of R$247.9 million, versus R$179.2 million in 2021, as interest expense rose amid higher Brazilian rates and the preferred-share instrument. The effective tax rate fell to 8.3% from 11.4%, primarily reflecting changes in tax effects and unrecognized deferred tax assets.
Cash used in investing activities was R$591.5 million, mainly for acquisitions and investment in property and intangible assets. Cash from financing activities was R$92.9 million. The filing reports R$297.0 million of capital expenditures in 2022 and a 2023 budget of R$225.6 million. Current assets were R$1,637.7 million and current liabilities R$905.7 million at year-end. These figures imply working capital of about R$732 million and a current ratio of about 1.8x.
Loans and financing include R$824.3 million associated with SoftBank’s Series A perpetual convertible preferred shares, classified as a financial liability under IFRS, and R$499.8 million of debentures. Lease liabilities were R$769.5 million; amounts payable to selling shareholders were R$528.7 million. The debentures require net debt (excluding the preferred shares and lease liabilities) to Adjusted EBITDA of no more than 3.0x; Afya reported compliance at year-end.
Material changes versus prior periods
- Revenue grew 35.5%; management attributed approximately 48% of 2022 revenue growth to acquisitions and 52% to organic growth. Revenue growth excluding acquisitions was reported as 18.5%.
- Undergraduate revenue rose 36.0%, supported by seat maturation, a 9.1% increase in the medical-program average monthly ticket to R$9,400, and acquired businesses. Cost of services grew more slowly than revenue, lowering its share of revenue to 36.9% from 37.9%.
- Continuing Education revenue rose 49.1%, with active paying students increasing 34.2% to 4,280 as in-person activities resumed.
- Digital Services revenue rose 25.0%, including contributions from 2022 acquisitions. Management cited stronger B2B activity and active payers, partly offset by weaker Medcel performance amid greater residency-preparation competition.
- Operating income and net income increased, while finance expense also increased substantially. Operating cash flow rose, but cash conversion declined from 100.8% to 94.4%.
- Net investing cash outflow decreased from R$1,274.1 million to R$591.5 million, chiefly because acquisition spending was lower than in 2021. Afya issued R$500 million of debentures in December 2022 to support general corporate purposes, liquidity and debt-maturity extension.
Outlook, commentary, risks and unusual items
- Outlook: Afya said existing cash and operating cash flows should cover ordinary working-capital needs and capital expenditures for the next 12 months. It gave no formal revenue or earnings guidance. The company expects growth from medical-seat maturation, tuition increases, digital and continuing-education expansion, and selective acquisitions. Management estimated medical-student capacity could reach roughly 22,700 by 2028, subject to regulatory requirements and campus maturation.
- Regulation and competition: In April 2023, after the reporting date, Brazil’s education ministry revoked the five-year suspension on authorizing new medical courses and established a new public-call process. New seats could increase competition and pressure tuition, costs or occupancy. Court challenges to the rules add uncertainty.
- Acquisitions and subsequent event: Three digital businesses were acquired in 2022 for aggregate consideration of about R$99.4 million. DelRey, acquired on January 2, 2023, had a stated purchase price of R$825 million before net debt, with additional potential payment tied to seat approvals; it is not included in 2022 results.
- Key business risks: Concentration in medical and health-sciences tuition; student affordability and payment defaults; changes or delays in FIES financing and loss of PROUNI tax benefits; regulatory approvals and education quality; acquisition integration and goodwill impairment; competition, technology and cybersecurity; and Brazilian inflation, interest rates, political conditions and currency movements. The real appreciated 6.5% against the U.S. dollar in 2022, but currency volatility remains a risk.
- Liquidity and obligations: Contractual undiscounted obligations totaled R$4,913.1 million, including leases, financing, selling-shareholder payments, notes and customer advances. The filing reported no off-balance-sheet arrangements. Preferred shares carry a cumulative 6.5% annual dividend and specified conversion and redemption rights.
- Legal matters: Provisions for probable legal losses were R$195.9 million, mainly tax matters; possible losses not provisioned totaled R$78.4 million. Afya also recorded R$145.3 million of indemnification assets relating to certain acquisition-related contingencies. Management considers legal outcomes uncertain.
- Unusual items and controls: Afya invoiced R$9.9 million in 2022 for prior-period tuition discounts related to COVID-19, net of discounts and provisions. Auditors issued unqualified opinions on the IFRS financial statements and internal controls; management reported effective controls, although controls at three 2022 acquisitions were excluded from the year-end assessment. A critical audit matter concerned fair-value estimates for acquired intangible assets.
Most important facts for investors to verify
- How much of reported growth is sustainable organic growth versus acquisition contributions, and whether student counts and medical-seat maturation support future revenue.
- Cash generation after capital expenditures, acquisition payments, lease commitments and seller payments; also the sensitivity of debt costs to CDI and other Brazilian rates.
- Debenture covenant headroom and the treatment, cash cost and potential dilution associated with SoftBank’s preferred shares.
- Regulatory outcomes for new medical-course authorizations, existing campuses and seat approvals, including the effect on competition and tuition pricing.
- Collection of tuition receivables, FIES exposure, recovery of COVID-era discounts, and the adequacy of legal provisions and related indemnification assets.
- The integration and performance of acquired digital businesses, including whether acquisition-related goodwill and intangible-asset values remain supportable.